A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives-Reference-Cited by-同舟云学术

A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives

Published:2015-06-12 Issue:29 Volume:6 Page:26814-26825
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Russo Alessandro¹,Franchina Tindara¹,Rita Ricciardi Giuseppina Rosaria¹,Picone Antonio¹,Ferraro Giuseppa¹,Zanghì Mariangela¹,Toscano Giuseppe¹,Giordano Antonio²,Adamo Vincenzo¹

Affiliation:

1. Medical Oncology Unit AOOR Papardo-Piemonte & Department of Human Pathology, University of Messina, Messina, Italy

2. Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, Temple University, Philadelphia, Pennsylvania, USA

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 150 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic advances of targeting receptor tyrosine kinases in cancer;Signal Transduction and Targeted Therapy;2024-08-14

2. Cross-attention enables deep learning on limited omics-imaging-clinical data of 130 lung cancer patients;Cell Reports Methods;2024-07

3. DB-1310, an ADC comprised of a novel anti-HER3 antibody conjugated to a DNA topoisomerase I inhibitor, is highly effective for the treatment of HER3-positive solid tumors;Journal of Translational Medicine;2024-04-17

4. Emerging Therapies for Glioblastoma;Cancers;2024-04-12

5. The difference between dacomitinib and afatinib in effectiveness and safety in first-line treatment of patients with advanced EGFR-mutant non-small cell lung cancer: a real-world observational study;BMC Cancer;2024-02-19